Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15


TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer.

Dufour F, Silina L, Neyret-Kahn H, Moreno-Vega A, Krucker C, Karboul N, Dorland-Galliot M, Maillé P, Chapeaublanc E, Allory Y, Stransky N, Haegel H, Menguy T, Duong V, Radvanyi F, Bernard-Pierrot I.

Br J Cancer. 2019 Mar;120(5):555-564. doi: 10.1038/s41416-019-0397-6. Epub 2019 Feb 15.


Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models.

Menguy T, Briaux A, Jeunesse E, Giustiniani J, Calcei A, Guyon T, Mizrahi J, Haegel H, Duong V, Soler V, Brousset P, Bensussan A, Raymond Letron I, Le Bouteiller P.

Invest Ophthalmol Vis Sci. 2018 Jun 1;59(7):2687-2698. doi: 10.1167/iovs.18-24024.


Bone- and cartilage-protective effects of a monoclonal antibody against colony-stimulating factor 1 receptor in experimental arthritis.

Toh ML, Bonnefoy JY, Accart N, Cochin S, Pohle S, Haegel H, De Meyer M, Zemmour C, Preville X, Guillen C, Thioudellet C, Ancian P, Lux A, Sehnert B, Nimmerjahn F, Voll RE, Schett G.

Arthritis Rheumatol. 2014 Nov;66(11):2989-3000. doi: 10.1002/art.38624.


3D modeling and characterization of the human CD115 monoclonal antibody H27K15 epitope and design of a chimeric CD115 target.

Grellier B, Le Pogam F, Vitorino M, Starck JP, Geist M, Duong V, Haegel H, Menguy T, Bonnefoy JY, Marchand JB, Ancian P.

MAbs. 2014 Mar-Apr;6(2):533-46. doi: 10.4161/mabs.27736. Epub 2014 Jan 6.


Therapeutic effects of anti-CD115 monoclonal antibody in mouse cancer models through dual inhibition of tumor-associated macrophages and osteoclasts.

Fend L, Accart N, Kintz J, Cochin S, Reymann C, Le Pogam F, Marchand JB, Menguy T, Slos P, Rooke R, Fournel S, Bonnefoy JY, Préville X, Haegel H.

PLoS One. 2013 Sep 3;8(9):e73310. doi: 10.1371/journal.pone.0073310. eCollection 2013.


A unique anti-CD115 monoclonal antibody which inhibits osteolysis and skews human monocyte differentiation from M2-polarized macrophages toward dendritic cells.

Haegel H, Thioudellet C, Hallet R, Geist M, Menguy T, Le Pogam F, Marchand JB, Toh ML, Duong V, Calcei A, Settelen N, Preville X, Hennequi M, Grellier B, Ancian P, Rissanen J, Clayette P, Guillen C, Rooke R, Bonnefoy JY.

MAbs. 2013 Sep-Oct;5(5):736-47. doi: 10.4161/mabs.25743. Epub 2013 Jul 15.


TLR2 ligation protects effector T cells from regulatory T-cell mediated suppression and repolarizes T helper responses following MVA-based cancer immunotherapy.

Amiset L, Fend L, Gatard-Scheikl T, Rittner K, Duong V, Rooke R, Muller S, Bonnefoy JY, Préville X, Haegel H.

Oncoimmunology. 2012 Nov 1;1(8):1271-1280.


Adenovirus-mediated gene transfer of pathogen-associated molecular patterns for cancer immunotherapy.

Tosch C, Geist M, Ledoux C, Ziller-Remi C, Paul S, Erbs P, Corvaia N, Von Hoegen P, Balloul JM, Haegel H.

Cancer Gene Ther. 2009 Apr;16(4):310-9. doi: 10.1038/cgt.2008.85. Epub 2008 Oct 24.


Lack of beta-catenin affects mouse development at gastrulation.

Haegel H, Larue L, Ohsugi M, Fedorov L, Herrenknecht K, Kemler R.

Development. 1995 Nov;121(11):3529-37.


Quantitative and qualitative changes in CD44 and MEL-14 expression by T cells in C57BL/6 mice during aging.

Barrat F, Haegel H, Louise A, Vincent-Naulleau S, Boulouis HJ, Neway T, Ceredig R, Pilet C.

Res Immunol. 1995 Jan;146(1):23-34.


Fast screening of mouse mutants generated after homologous recombination.

Felthaus J, Haegel H, Larue L.

Nucleic Acids Res. 1994 Dec 11;22(24):5504-5. No abstract available.


Supplemental Content

Loading ...
Support Center